pti5803

PTI5803 is a **patent-protected, orally administered small molecule drug** developed by PannTheraPi for use in neurology. Its primary mechanism is **selective modulation of the pannexin 1 channel** (Panx1), a drug target implicated in certain forms of epilepsy, including Focal Cortical Dysplasia (FCD), a rare epileptic syndrome. Research conducted by the company's founders at the University of Paris Sciences et Lettres (PSL) has demonstrated the involvement of the pannexin 1 channel in epilepsy. The drug has completed Phase 1 safety studies in healthy volunteers with positive results and is being prepared for a Phase IIa trial for patients with resistant epilepsy and Focal Cortical Dysplasia[1][2][3][9].

Brand names

pti5803pti-5803pti 5803

Other names

pti5803pti-5803pti 5803